107 related articles for article (PubMed ID: 11549430)
1. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis.
Neymark N; Adriaenssen I; Gorlia T; Caleo S; Bolla M; Brochon D
Eur J Cancer; 2001 Sep; 37(14):1768-74. PubMed ID: 11549430
[TBL] [Abstract][Full Text] [Related]
2. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer.
Neymark N; Adriaenssen I; Gorlia T; Caleo S; Bolla M
Health Econ; 2002 Apr; 11(3):233-48. PubMed ID: 11921320
[TBL] [Abstract][Full Text] [Related]
3. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
Samant RS; Dunscombe PB; Roberts GH
Urol Oncol; 2003; 21(3):171-7. PubMed ID: 12810202
[TBL] [Abstract][Full Text] [Related]
4. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
Nygård R; Norum J; Due J
Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
[TBL] [Abstract][Full Text] [Related]
5. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
6. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
Iannazzo S; Pradelli L; Carsi M; Perachino M
Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer.
Cheng TF; Wang JD; Uen WC
BMC Cancer; 2012 Jan; 12():33. PubMed ID: 22264299
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
11. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
Bolla M; Collette L; Blank L; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Mattelaer J; Lopez Torecilla J; Pfeffer JR; Lino Cutajar C; Zurlo A; Pierart M
Lancet; 2002 Jul; 360(9327):103-6. PubMed ID: 12126818
[TBL] [Abstract][Full Text] [Related]
12. A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents.
Sculpher M; Thompson E; Brown J; Garry R
BJOG; 2000 Mar; 107(3):340-6. PubMed ID: 10740330
[TBL] [Abstract][Full Text] [Related]
13. Advanced prostate cancer. The role of high priced hormone therapy.
Nicol DL; Heathcote PS; Kateley GD; Lloyd S
Med J Aust; 1993 Jul; 159(1):16-9. PubMed ID: 8316105
[TBL] [Abstract][Full Text] [Related]
14. Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors.
Utomo NB; Mochtar CA; Umbas R
Acta Med Indones; 2012 Jan; 44(1):10-5. PubMed ID: 22451179
[TBL] [Abstract][Full Text] [Related]
15. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
16. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
Anderson PR; Hanlon AL; Movsas B; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
[TBL] [Abstract][Full Text] [Related]
20. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
